Aurobindo Pharma Ltd (AUROPHARMA) Q3FY25 Concall Summary - Dec-2024 Qtr
Performance Overview
- Aurobindo Pharma achieved its highest-ever quarterly revenue of 7,979 crores, demonstrating robust growth both year-on-year and quarter-on-quarter.
- Strong base product sales in the U.S., sustained momentum in Europe, and expansion in high-growth markets fueled this performance.
- Impressive volume growth, successful product launches, and stable pricing contributed to the strong quarter.
- Gross contribution reached its highest level at 4,663 crores, with gross margins increasing by 130 bps year-on-year to 58.4% despite lower transient sales.
- EBITDA stood at 1,628 crores with a 20.4% margin, even with a 50 crore increase in R&D spending compared to Q3 FY24.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.